#1 Clinical Trials Search in Europe

Midomafetamine Hydrochloride

This article explores a clinical trial investigating the use of MDMA-assisted therapy for patients with treatment-resistant posttraumatic stress disorder (PTSD). The study aims to evaluate the effectiveness of a high-intensity inpatient approach using MDMA (also known as Midomafetamine Hydrochloride) in combination with psychotherapy to treat PTSD symptoms and improve functional outcomes in patients who have not responded to previous treatments.

Table of Contents

What is MDMA (Midomafetamine Hydrochloride)?

MDMA, also known as Midomafetamine Hydrochloride or 3,4-methylenedioxymethamphetamine hydrochloride, is a substance being studied for its potential therapeutic benefits in treating mental health conditions[1]. While it’s commonly known as a recreational drug, researchers are exploring its use in controlled medical settings to help patients with certain psychiatric disorders.

MDMA for PTSD Treatment

MDMA is being investigated as a potential treatment for Post-Traumatic Stress Disorder (PTSD), particularly for patients who haven’t responded well to other treatments[1]. PTSD is a mental health condition that can develop after experiencing or witnessing a traumatic event. It can cause severe anxiety, flashbacks, and difficulty in daily functioning.

Details of the Clinical Study

A clinical study is being conducted to evaluate the effectiveness of MDMA-assisted therapy for people with treatment-resistant PTSD[1]. This study is described as a “High-Intensity Inpatient MDMA-Assisted Psychotherapy for Treatment-Refractory Posttraumatic Stress Disorder: An Open-Label Pilot Study.” Here are some key points about the study:

  • It’s an exploratory study looking at the feasibility, safety, and effectiveness of using MDMA in a therapy setting for PTSD treatment.
  • The treatment is conducted in an inpatient setting, meaning participants stay in a medical facility during the treatment.
  • It’s specifically for people who haven’t responded well to at least two previous evidence-based trauma-focused psychotherapies.

Who Can Participate in the Study?

The study has specific criteria for who can participate[1]. Eligible participants must:

  • Be at least 18 years old
  • Meet the criteria for PTSD according to the DSM-5 (a diagnostic manual used by mental health professionals)
  • Have had PTSD symptoms for at least 6 months
  • Score 40 or higher on the PCL-5 (a test that measures PTSD severity)
  • Have tried at least two evidence-based trauma-focused psychotherapies, with at least 10 sessions each, without sufficient improvement

Who Cannot Participate in the Study?

For safety reasons, certain individuals are not eligible to participate in the study[1]. This includes people who:

  • Have a current Personality Disorder
  • Have uncontrolled high blood pressure
  • Have a current eating disorder with compensatory behaviors
  • Have major depression with psychotic features
  • Have a history of or current primary psychotic disorder or bipolar disorder type 1
  • Have moderate to severe alcohol or cannabis use disorder within the past year
  • Have any active illicit drug use disorder (other than cannabis) in the past year
  • Are at serious risk of suicide
  • Have certain heart conditions or a history of heart problems

What Does the Study Aim to Achieve?

The main goals of this study are[1]:

  1. To evaluate how MDMA-assisted therapy affects PTSD symptoms
  2. To assess how this therapy impacts the patient’s overall functioning in daily life
  3. To determine if a high-intensity inpatient approach to MDMA-assisted therapy is feasible

How is the Treatment Administered?

The treatment involves taking MDMA in capsule form under medical supervision[1]. The study uses two different dosages:

  • One capsule contains up to 60 mg of MDMA, with a maximum daily dose of 60 mg
  • Another capsule contains up to 120 mg of MDMA, with a maximum daily dose of 120 mg and a maximum total dose of 240 mg over two days

The treatment is given orally (by mouth) and is combined with psychotherapy sessions.

Potential Benefits of MDMA-Assisted Therapy

While the study is still ongoing and results are not yet known, researchers hope that MDMA-assisted therapy might offer benefits for people with treatment-resistant PTSD[1]. Potential benefits being studied include:

  • Reduction in PTSD symptoms
  • Improvement in daily functioning
  • A new treatment option for those who haven’t responded to other therapies

It’s important to note that this is a research study, and MDMA is not currently approved for general medical use in treating PTSD. The safety and effectiveness of this treatment are still being evaluated.

Aspect Details
Study Title High-Intensity Inpatient MDMA-Assisted Psychotherapy for Treatment-Refractory Posttraumatic Stress Disorder: An Open-Label Pilot Study
Primary Objective Evaluate the effect of MDMA-assisted therapy on PTSD symptoms
Secondary Objectives 1. Evaluate effect on clinician-rated functional impairment
2. Assess feasibility of high-intensity inpatient approach
Key Inclusion Criteria 1. Age 18 or older
2. Current PTSD (DSM-5 criteria) for at least 6 months
3. PCL-5 score ≥ 40
4. Treatment-refractory PTSD
Key Exclusion Criteria 1. Current personality disorder
2. Uncontrolled hypertension
3. Current eating disorder with compensatory behaviors
4. Major depressive disorder with psychotic features
5. History of psychotic disorders or bipolar disorder type 1
Primary Endpoint Mean change in CAPS-5 Total Severity Score from Baseline to 12 weeks post-Baseline
Drug Information 1. Name: Midomafetamine Hydrochloride (MDMA HCl)
2. Form: Capsule
3. Route: Oral
4. Max daily dose: 60-120 mg
5. Max total dose: 60-240 mg

FAQ

  • What is the main purpose of this clinical trial? The main purpose of this clinical trial is to evaluate the effect of MDMA-assisted therapy on PTSD symptoms in patients with treatment-resistant PTSD.
  • Who is eligible to participate in this study? Eligible participants must be at least 18 years old, meet DSM-5 criteria for current PTSD with symptoms lasting at least 6 months, have a PCL-5 score of 40 or greater, and have undergone at least two evidence-based trauma-focused psychotherapies of at least 10 sessions each without success.
  • What is the treatment approach being studied? The study is investigating a high-intensity inpatient approach to MDMA-assisted therapy. This involves administering MDMA (Midomafetamine Hydrochloride) in capsule form along with psychotherapy in an inpatient setting.
  • What are some of the exclusion criteria for this study? Some exclusion criteria include having a current personality disorder, uncontrolled hypertension, current eating disorder with compensatory behaviors, major depressive disorder with psychotic features, history of psychotic disorders or bipolar disorder type 1, and certain substance use disorders.
  • How will the effectiveness of the treatment be measured? The primary measure of effectiveness will be the mean change in CAPS-5 Total Severity Score from baseline to 12 weeks post-baseline. Secondary measures include changes in functional impairment using the Sheehan Disability Scale and assessment of the feasibility of the inpatient approach.

Ongoing Clinical Trials on Midomafetamine Hydrochloride

  • Study on MDMA-Assisted Therapy for Patients with Treatment-Resistant PTSD

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

Glossary

  • PTSD: Post-Traumatic Stress Disorder, a mental health condition triggered by experiencing or witnessing a terrifying event, characterized by symptoms such as flashbacks, nightmares, and severe anxiety.
  • MDMA: 3,4-Methylenedioxymethamphetamine, also known as Midomafetamine Hydrochloride, a psychoactive drug being studied for its potential therapeutic effects in combination with psychotherapy.
  • Treatment-resistant PTSD: A condition where PTSD symptoms persist despite having undergone multiple evidence-based trauma-focused psychotherapies.
  • DSM-5: Diagnostic and Statistical Manual of Mental Disorders, 5th edition, a standard classification of mental disorders used by mental health professionals.
  • PCL-5: PTSD Checklist for DSM-5, a self-report measure used to assess the presence and severity of PTSD symptoms.
  • CAPS-5: Clinician-Administered PTSD Scale for DSM-5, a structured interview used to make current and lifetime PTSD diagnoses and assess symptom severity.
  • Sheehan Disability Scale (SDS): A patient-reported outcome measure used to assess functional impairment in work/school, social, and family life.
  • Psychotherapy: A type of therapy that involves talking with a mental health professional to treat mental illness and emotional difficulties.
  • Inpatient approach: A treatment method where patients are admitted to a hospital or clinic for round-the-clock care and monitoring during the course of treatment.
  • Sympathomimetic drug: A type of drug that mimics the effects of the sympathetic nervous system, potentially increasing heart rate and blood pressure.

References

  1. http://clinicaltrials.eu/trial/study-on-mdma-assisted-therapy-for-patients-with-treatment-resistant-ptsd/